BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 37703185)

  • 1. Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach.
    Schott CR; Koehne AL; Sayles LC; Young EP; Luck C; Yu K; Lee AG; Breese MR; Leung SG; Xu H; Shah AT; Liu HY; Spillinger A; Behroozfard IH; Marini KD; Dinh PT; Pons Ventura MV; Vanderboon EN; Hazard FK; Cho SJ; Avedian RS; Mohler DG; Zimel M; Wustrack R; Curtis C; Sirota M; Sweet-Cordero EA
    Clin Cancer Res; 2024 Feb; 30(4):849-864. PubMed ID: 37703185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and characterization of new patient-derived xenograft (PDX) models of osteosarcoma with distinct metastatic capacities.
    Schott CR; Koehne AL; Sayles LC; Young EP; Luck C; Yu K; Lee AG; Breese MR; Leung SG; Xu H; Shah AT; Liu HY; Spillinger A; Behroozfard IH; Marini KD; Dinh PT; Pons Ventura MAV; Vanderboon EN; Hazard FK; Cho SJ; Avedian RS; Mohler DG; Zimel M; Wustrack R; Curtis C; Sirota M; Sweet-Cordero EA
    bioRxiv; 2023 Jan; ():. PubMed ID: 36711882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tegavivint and the β-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma.
    Nomura M; Rainusso N; Lee YC; Dawson B; Coarfa C; Han R; Larson JL; Shuck R; Kurenbekova L; Yustein JT
    J Natl Cancer Inst; 2019 Nov; 111(11):1216-1227. PubMed ID: 30793158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinatorial screening using orthotopic patient derived xenograft-expanded early phase cultures of osteosarcoma identify novel therapeutic drug combinations.
    Loh AHP; Stewart E; Bradley CL; Chen X; Daryani V; Stewart CF; Calabrese C; Funk A; Miller G; Karlstrom A; Krafcik F; Goshorn DR; Vogel P; Bahrami A; Shelat A; Dyer MA
    Cancer Lett; 2019 Feb; 442():262-270. PubMed ID: 30395907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9.
    Saqub H; Proetsch-Gugerbauer H; Bezrookove V; Nosrati M; Vaquero EM; de Semir D; Ice RJ; McAllister S; Soroceanu L; Kashani-Sabet M; Osorio R; Dar AA
    Sci Rep; 2020 Oct; 10(1):18489. PubMed ID: 33116269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations.
    Nanni P; Landuzzi L; Manara MC; Righi A; Nicoletti G; Cristalli C; Pasello M; Parra A; Carrabotta M; Ferracin M; Palladini A; Ianzano ML; Giusti V; Ruzzi F; Magnani M; Donati DM; Picci P; Lollini PL; Scotlandi K
    Sci Rep; 2019 Aug; 9(1):12174. PubMed ID: 31434953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma.
    Landuzzi L; Manara MC; Lollini PL; Scotlandi K
    Cells; 2021 Feb; 10(2):. PubMed ID: 33671173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation and characterization of patient-derived xenografts from patients with osteosarcoma.
    Chen F; Zhang Z; Shen R; Chen M; Li G; Zhu X
    Tissue Cell; 2022 Dec; 79():101911. PubMed ID: 36156374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium.
    Gill J; Zhang W; Zhang Z; Roth M; Harrison DJ; Rowshan S; Erickson S; Gatto G; Kurmasheva R; Houghton P; Teicher B; Smith MA; Kolb EA; Gorlick R
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28606. PubMed ID: 32706456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with
    Nelson LJ; Castro KE; Xu B; Li J; Dinh NB; Thompson JM; Woytash J; Kipp KR; Razorenova OV
    Cell Cycle; 2022 May; 21(10):1103-1119. PubMed ID: 35240916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity.
    Zucchini C; Manara MC; Cristalli C; Carrabotta M; Greco S; Pinca RS; Ferrari C; Landuzzi L; Pasello M; Lollini PL; Gambarotti M; Donati DM; Scotlandi K
    J Exp Clin Cancer Res; 2019 Dec; 38(1):503. PubMed ID: 31878963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-Derived Xenograft Models for Translational Prostate Cancer Research and Drug Development.
    Philp LK
    Methods Mol Biol; 2024; 2806():153-185. PubMed ID: 38676802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6-Cyclin D-Rb pathway.
    Wang D; Bao H
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):31-40. PubMed ID: 34655298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of Patient-Derived Xenograft Mouse Model with Human Osteosarcoma Tissues.
    Sun X; Chang J; Zhou C; Zhao P; Guo S; Tong J; Wang Y; Yang Y
    J Vis Exp; 2024 Mar; (205):. PubMed ID: 38587398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterotypic mouse models of canine osteosarcoma recapitulate tumor heterogeneity and biological behavior.
    Scott MC; Tomiyasu H; Garbe JR; Cornax I; Amaya C; O'Sullivan MG; Subramanian S; Bryan BA; Modiano JF
    Dis Model Mech; 2016 Dec; 9(12):1435-1444. PubMed ID: 27874835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models.
    Jian C; Tu MJ; Ho PY; Duan Z; Zhang Q; Qiu JX; DeVere White RW; Wun T; Lara PN; Lam KS; Yu AX; Yu AM
    Oncotarget; 2017 May; 8(19):30742-30755. PubMed ID: 28415566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the metastatic phenotype of a panel of established osteosarcoma cells.
    Ren L; Mendoza A; Zhu J; Briggs JW; Halsey C; Hong ES; Burkett SS; Morrow J; Lizardo MM; Osborne T; Li SQ; Luu HH; Meltzer P; Khanna C
    Oncotarget; 2015 Oct; 6(30):29469-81. PubMed ID: 26320182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An association between successful engraftment of osteosarcoma patient-derived xenografts and clinicopathological findings.
    Fortuna-Costa A; Granato RA; Meohas W; Lopes ACS; Caruso AC; Castro E Silva Pinheiro R; d'Eça PDG; Dias RB; Perini JA; Barbosa APF; Moreira de Sá RA; Guimarães JAM; Murray SS; Duarte MEL
    Histol Histopathol; 2020 Nov; 35(11):1295-1307. PubMed ID: 32964941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma.
    McGuire JJ; Nerlakanti N; Lo CH; Tauro M; Utset-Ward TJ; Reed DR; Lynch CC
    Int J Cancer; 2020 Nov; 147(10):2811-2823. PubMed ID: 32599665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of intraarterial and intravenous cisplatin chemotherapy in the treatment of metastatic osteosarcoma using an orthotopic xenograft mouse model.
    Robl B; Botter SM; Pellegrini G; Neklyudova O; Fuchs B
    J Exp Clin Cancer Res; 2016 Jul; 35(1):113. PubMed ID: 27421768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.